Truist Securities Reiterates Buy on Regeneron Pharmaceuticals, Maintains $1045 Price Target
Portfolio Pulse from richadhand@benzinga.com
Truist Securities analyst Robyn Karnauskas has reiterated a 'Buy' rating on Regeneron Pharmaceuticals (NASDAQ:REGN) and maintained a price target of $1045.
August 21, 2023 | 1:56 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Regeneron Pharmaceuticals has received a reiterated 'Buy' rating from Truist Securities, with a maintained price target of $1045.
The reiterated 'Buy' rating and maintained price target by Truist Securities indicates a positive outlook for Regeneron Pharmaceuticals. This could potentially lead to an increase in investor confidence and a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100